ABSI
Absci Corporation [ABSI] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ABSI Stock Summary
Top 10 Correlated ETFs
ABSI
Top 10 Correlated Stocks
ABSI
In the News
ABSI Financial details
Company Rating
Sell
Market Cap
657.54M
Income
-110.57M
Revenue
5.72M
Book val./share
1.9
Cash/share
1.23
Dividend
-
Dividend %
-
Employees
155
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-3.56
Forward P/E
-
PEG
-8.19
P/S
55.06
P/B
1.93
P/C
4.05
P/FCF
-6.88
Quick Ratio
4.09
Current Ratio
4.82
Debt / Equity
0.06
LT Debt / Equity
0.03
-
-
EPS (TTM)
-1.2
EPS next Y
-
EPS next Q
-
EPS this Y
4.35%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
74.72%
Revenue last 5Y
22.65%
Revenue Q/Q
-54.57%
EPS Q/Q
4.17%
-
-
-
-
SMA20
20%
SMA50
50%
SMA100
500%
Inst Own
25.64%
Inst Trans
0.69%
ROA
-45%
ROE
-45%
ROC
-0.54%
Gross Margin
100%
Oper. Margin
-1613%
Profit Margin
-1535%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.111-6.72
52W High
-16.92%
52W Low
+398.5%
RSI
45
Rel Volume
0.58
Avg Volume
1.57M
Volume
912.74K
Perf Week
-18.01%
Perf Month
-2.83%
Perf Quarter
333.48%
Perf Half Y
248.6%
-
-
-
-
Beta
2.367
-
-
Volatility
0.34%, 0.45%
Prev Close
-5.77%
Price
4.985
Change
-8.56%
ABSI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.02 | 0.05 | 0.05 | 0.06 | 0.06 | |
| Net income per share | -0.07 | -0.16 | -1.09 | -1.15 | -1.2 | |
| Operating cash flow per share | -0.07 | -0.12 | -0.65 | -0.9 | -0.7 | |
| Free cash flow per share | -0.08 | -0.14 | -1.06 | -1.07 | -0.71 | |
| Cash per share | 0.14 | 0.76 | 2.73 | 1.81 | 1.24 | |
| Book value per share | -0.45 | -0.97 | 3.95 | 3.02 | 1.91 | |
| Tangible book value per share | -0.45 | -0.97 | 3.13 | 2.22 | 1.39 | |
| Share holders equity per share | -0.45 | -0.97 | 3.95 | 3.02 | 1.91 | |
| Interest debt per share | 0.07 | 0.16 | 0.25 | 0.26 | 0.12 | |
| Market cap | 1.99B | 1.99B | 759.71M | 190.78M | 386.52M | |
| Enterprise value | 1.98B | 1.94B | 527.16M | 153.8M | 313.92M | |
| P/E ratio | -292.85 | -136.71 | -7.52 | -1.82 | -3.5 | |
| Price to sales ratio | 966.83 | 416.67 | 158.87 | 33.2 | 67.6 | |
| POCF ratio | -330.19 | -181.56 | -12.54 | -2.35 | -5.98 | |
| PFCF ratio | -279.34 | -151.45 | -7.7 | -1.96 | -5.9 | |
| P/B Ratio | -48.39 | -22.27 | 2.08 | 0.7 | 2.19 | |
| PTB ratio | -48.39 | -22.27 | 2.08 | 0.7 | 2.19 | |
| EV to sales | 963.4 | 405.09 | 110.24 | 26.76 | 54.9 | |
| Enterprise value over EBITDA | -340.71 | -153.82 | -5.28 | -1.68 | -3.94 | |
| EV to operating cash flow | -329.01 | -176.51 | -8.7 | -1.89 | -4.86 | |
| EV to free cash flow | -278.35 | -147.24 | -5.34 | -1.58 | -4.79 | |
| Earnings yield | 0 | -0.01 | -0.13 | -0.55 | -0.29 | |
| Free cash flow yield | 0 | -0.01 | -0.13 | -0.51 | -0.17 | |
| Debt to equity | -0.15 | -0.16 | 0.05 | 0.08 | 0.06 | |
| Debt to assets | 0.31 | 0.16 | 0.05 | 0.07 | 0.04 | |
| Net debt to EBITDA | 1.21 | 4.4 | 2.33 | 0.4 | 0.91 | |
| Current ratio | 3.94 | 7.25 | 8.07 | 6.17 | 4.08 | |
| Interest coverage | -23.38 | -20.98 | -21.92 | -109.83 | -92.75 | |
| Income quality | 0.92 | 0.76 | 0.6 | 0.78 | 0.58 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 2.09 | 2.39 | 9.32 | 10.25 | 8.32 | |
| Intangibles to total assets | 0.01 | 0 | 0.18 | 0.23 | 0.21 | |
| Capex to operating cash flow | 0.18 | 0.2 | 0.63 | 0.2 | 0.01 | |
| Capex to revenue | -0.53 | -0.46 | -7.96 | -2.81 | -0.15 | |
| Capex to depreciation | -2.24 | -1.93 | -5.72 | -1.24 | -0.06 | |
| Stock based compensation to revenue | 0.02 | 0.09 | 2.22 | 2.18 | 2 | |
| Graham number | 0.86 | 1.86 | 9.84 | 8.86 | 7.19 | |
| ROIC | 0.2 | 0.2 | -0.17 | -0.34 | -0.49 | |
| Return on tangible assets | -0.35 | -0.16 | -0.29 | -0.42 | -0.59 | |
| Graham Net | -0.51 | -1.16 | 2.15 | 1.39 | 0.62 | |
| Working capital | 10.18M | 63.14M | 239.22M | 156.59M | 91.02M | |
| Tangible asset value | -41.44M | -89.62M | 289.78M | 201.46M | 127.92M | |
| Net current asset value | -46.98M | -104.76M | 212.99M | 140.27M | 62.27M | |
| Invested capital | -0.15 | -0.16 | 0.05 | 0.08 | 0.06 | |
| Average receivables | 0 | 908K | 1.51M | 1.49M | 1.87M | |
| Average payables | 0 | 1.19M | 5.25M | 5.4M | 1.96M | |
| Average inventory | 0 | 1 | 5.26M | 12.77M | 7.51M | |
| Days sales outstanding | 39.33 | 121.72 | 108.77 | 98.44 | 139.73 | |
| Days payables outstanding | 22.69 | 67.47 | 459.95 | 67.53 | 39.19 | |
| Days of inventory on hand | 0 | 0 | 576.68 | 420.6 | 0 | |
| Receivables turnover | 9.28 | 3 | 3.36 | 3.71 | 2.61 | |
| Payables turnover | 16.09 | 5.41 | 0.79 | 5.41 | 9.31 | |
| Inventory turnover | 4.31M | 11.45M | 0.63 | 0.87 | 0 | |
| ROE | 0.17 | 0.16 | -0.28 | -0.38 | -0.63 | |
| Capex per share | -0.01 | -0.02 | -0.41 | -0.18 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.02 | 0.01 | 0.04 | 0.01 | 0 | |
| Net income per share | -0.21 | -0.26 | -0.45 | -0.24 | -0.25 | |
| Operating cash flow per share | -0.2 | -0.22 | -0.21 | -0.11 | -0.16 | |
| Free cash flow per share | -0.21 | -0.22 | -0.21 | -0.12 | -0.16 | |
| Cash per share | 1.8 | 1.58 | 1.36 | 1.23 | 1.23 | |
| Book value per share | 3 | 2.78 | 2.35 | 2.13 | 1.9 | |
| Tangible book value per share | 2.21 | 1.99 | 1.8 | 1.6 | 1.38 | |
| Share holders equity per share | 3 | 2.78 | 2.35 | 2.13 | 1.9 | |
| Interest debt per share | 0.25 | 0.24 | 0.21 | 0.19 | 0.11 | |
| Market cap | 191.77M | 160.09M | 139.58M | 121.73M | 388.81M | |
| Enterprise value | 154.8M | 169.92M | 98M | 69.74M | 316.21M | |
| P/E ratio | -2.46 | -1.71 | -0.84 | -1.38 | -4.13 | |
| Price to sales ratio | 123.17 | 126.15 | 41.45 | 163.61 | 1.15K | |
| POCF ratio | -10.33 | -7.96 | -7.26 | -11.75 | -26.06 | |
| PFCF ratio | -10.03 | -7.85 | -7.16 | -11.41 | -26.03 | |
| P/B Ratio | 0.7 | 0.63 | 0.65 | 0.62 | 2.21 | |
| PTB ratio | 0.7 | 0.63 | 0.65 | 0.62 | 2.21 | |
| EV to sales | 99.42 | 133.9 | 29.11 | 93.74 | 935.53 | |
| Enterprise value over EBITDA | -9.62 | -8.7 | -5.91 | -3.83 | -15.24 | |
| EV to operating cash flow | -8.34 | -8.45 | -5.09 | -6.73 | -21.19 | |
| EV to free cash flow | -8.09 | -8.33 | -5.03 | -6.54 | -21.17 | |
| Earnings yield | -0.1 | -0.15 | -0.3 | -0.18 | -0.06 | |
| Free cash flow yield | -0.1 | -0.13 | -0.14 | -0.09 | -0.04 | |
| Debt to equity | 0.08 | 0.08 | 0.09 | 0.09 | 0.06 | |
| Debt to assets | 0.07 | 0.07 | 0.08 | 0.08 | 0.04 | |
| Net debt to EBITDA | 2.3 | -0.5 | 2.51 | 2.85 | 3.5 | |
| Current ratio | 6.17 | 6.08 | 5.81 | 4.82 | 4.08 | |
| Interest coverage | -73.49 | -76.28 | -167.92 | -101.76 | -118.82 | |
| Income quality | 0.95 | 0.86 | 0.46 | 0.47 | 0.63 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 7.27 | 9.97 | 3.6 | 14.82 | 34.82 | |
| Intangibles to total assets | 0.23 | 0.24 | 0.2 | 0.21 | 0.21 | |
| Capex to operating cash flow | 0.03 | 0.01 | 0.01 | 0.03 | 0 | |
| Capex to revenue | -0.36 | -0.22 | -0.08 | -0.41 | -0.05 | |
| Capex to depreciation | -0.16 | -0.08 | -0.07 | -0.09 | 0 | |
| Stock based compensation to revenue | 0.66 | 2.09 | 0.9 | 3.42 | 9.41 | |
| Graham number | 3.8 | 3.99 | 4.89 | 3.38 | 3.3 | |
| ROIC | -0.07 | -0.09 | -0.18 | -0.1 | -0.13 | |
| Return on tangible assets | -0.08 | -0.1 | -0.2 | -0.12 | -0.13 | |
| Graham Net | 1.39 | 1.21 | 1.04 | 0.89 | 0.62 | |
| Working capital | 156.59M | 138.12M | 122.55M | 106.74M | 91.02M | |
| Tangible asset value | 201.46M | 181.85M | 165.46M | 147.32M | 127.92M | |
| Net current asset value | 140.27M | 123.47M | 109.28M | 94.79M | 62.27M | |
| Invested capital | 0.08 | 0.08 | 0.09 | 0.09 | 0.06 | |
| Average receivables | 880K | 1.44M | 2.24M | 1.98M | 1.49M | |
| Average payables | 2.14M | 2.17M | 1.89M | 1.88M | 1.71M | |
| Average inventory | 15.02M | 15.03M | 15.05M | 15.55M | 8.02M | |
| Days sales outstanding | 89.6 | 94.04 | 84.39 | 96.77 | 582.87 | |
| Days payables outstanding | 60.54 | 49.65 | 47.62 | 48.91 | 38.83 | |
| Days of inventory on hand | 377.04 | 385.97 | 387.63 | 410.8 | 0 | |
| Receivables turnover | 1 | 0.96 | 1.07 | 0.93 | 0.15 | |
| Payables turnover | 1.49 | 1.81 | 1.89 | 1.84 | 2.32 | |
| Inventory turnover | 0.24 | 0.23 | 0.23 | 0.22 | 0 | |
| ROE | -0.07 | -0.09 | -0.19 | -0.11 | -0.13 | |
| Capex per share | -0.01 | 0 | 0 | 0 | 0 |
ABSI Frequently Asked Questions
What is Absci Corporation stock symbol ?
Absci Corporation is a US stock , located in Vancouver of Wa and trading under the symbol ABSI
What is Absci Corporation stock quote today ?
Absci Corporation stock price is $4.985 today.
Is Absci Corporation stock public?
Yes, Absci Corporation is a publicly traded company.
Company Profile
- Volume Average 1.57M
- Market Capitalization 657.54M
- Employee 155
- CEO Mr. Sean McClain
- Headquarters Vancouver,WA,US
- IPO Date 2021-07-22
-
Website
https://www.absci.com 
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
